cTnI as a predictor of cardiac death in cats with HCM | VETgirl Veterinary CE Podcasts

Hypertrophic cardiomyopathy (HCM) is the most common form of heart disease in cats and carries a particularly poor prognosis for those cats with HCM that experience aortic thromboembolism (ATE), congestive heart failure (CHF), and distortion of cardiac chamber dimensions and function. Assessment of cardiac biomarkers such as cardiac troponin I (cTnI) and N-terminal pro-B-type natriuretic peptide (NTproBNP) in various disease states has increased in human and veterinary medicine but little prognostic data is available for these biomarkers with HCM in cats. Both cardiac biomarkers appear to carry prognostic value in humans with HCM. So, Borgeat et al out of Royal Veterinary College wanted to investigated whether a single measurement of NTproBNP or cTnI would provide such value in cats with HCM in a study called Plasma Cardiac Troponin I Concentration and Cardiac Death in Cats with Hypertrophic Cardiomyopathy.